Granted Patent B2

US 12,544,463 · App. 17/384,998 · Granted Feb 10, 2026

Inventors: Zehui Wu (Philadelphia, PA); Zhihao Zha (Philadelphia, PA); Futao Liu (Philadelphia, PA); Karl Ploessl (Wilmington, DE); Seok Rye Choi (Aston, PA); Hank F. Kung (Springfield, PA)

Assignee: Five Eleven Pharma Inc.

A61K51/0455A61B6/037A61K51/04A61K51/0419A61K51/0431A61K51/0453C07B59/001C07B59/002C07B59/004C07C217/80C07C323/37C07D213/64C07D221/06C07D405/04C07D471/04C07B2200/05C07D277/66

Abstract

Claims (26)

1 . A compound of Formula I-A:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is methyl and is optionally substituted with one or more deuterium atoms;

X is —OTs; and

Y is (CD 2 ) 3 .

2 . The compound of claim 1 , having Formula I-B:

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , having Formula I-C:

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein R 1 is CD 3 .

5 . A compound having Formula II-B:

or a pharmaceutically acceptable salt thereof, wherein:

Y is —[O(CR a R b ) 2 ] m —, wherein R a and R b are each independently hydrogen or deuterium atoms;

X is —OTs;

R 2 is CD 3 ;

m is 3; and

A 1 is N or CH.

6 . The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein:

A 1 is N.

7 . The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein A 1 is CH.

8 . The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein Y is —[OCD 2 CD 2 ] 3 —.

9 . The compound of claim 5 , having Formula II-C:

or a pharmaceutically acceptable salt thereof, wherein:

A 1 is N or CH.

10 . The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein A 1 is N.

11 . The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein A 1 is CH.

Assignments (1)

Continuity (4)

References Cited (102)